U.S. markets closed

Editas Medicine, Inc. (EDIT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
35.88-0.28 (-0.77%)
At close: 4:00PM EDT
Sign in to post a message.
  • g
    grayfoxroving
    The whole market was down and more percentage-wise than EDIT. If you want an instant winner then try buying a lotto ticket or betting on the horses. It takes time to develop and phase test a biotech product but if the sickle cell work goes well this could be in the hundreds. I bought EXAS a few years back for 4-6 bucks when it announced a stool test for colon cancer. It took the next few years to get Cologuard on the market and it has soared. Lots of colon cancer patients. Lots of sickle cell patients. Please, no more bellyaching over a couple of days on any biotech. If you can't wait and can't sleep then buy Ford or a solar energy company. They sell a product. You have to wait for EDIT to pass a few more phase test levels and then see if you won.
  • i
    iamaverb
    Editas Medicine today announced that it named Chi Li, Ph.D., MBA, RAC, as the Company’s Senior Vice President and Chief Regulatory Officer, effective immediately. Dr. Li will lead regulatory affairs strategy and activities related to Editas Medicine’s drug development programs. Additionally, as previously announced, Dr. Mark S. Shearman, Ph.D., joined the Company today as Executive Vice President and Chief Scientific Officer. Drs. Shearman and Li strengthen the Company’s leadership team with a focus on advancing its pipeline of transformative, gene editing medicines to patients.
  • A
    Anonymous
    From some guy on ST: My sister is blind and is getting her eye treatment done July 11th and they are flying us out to Boston for the treatment, from what they have told us is that the four people who have gotten this treatment saw improvement with their vison and were able to identify a bar across a screen
  • P
    Pandora
    Shorting hedge funds and their media arms are trying to drive down the share price of gene-editing stocks, especially when those stocks do exceptionally well in a day or two. A ridiculous article came out three days ago claiming Intellia's stock was overvalued and then the share price plunged about ten dollars in one day. Intellia's stock is actually undervalued because it's our next great hope to cure cancer or specific kinds of cancer and genetic disease. These shorting hedge funds are illegally manipulating stocks in various ways. It's disgusting. Go Intellia, Editas, and Crispr.
    Bullish
  • A
    Anonymous
    Management needs to gain investor confidence to hold long term. When CEO states how partnerships are critical for EDITs success, he should back that up with a new major partnership. So, where is it?
  • A
    Anonymous
    Mullen was just granted a lot of options with a strike price of 45.69. It looks like it was granted due to achieving an “organizational milestone”. I really hope it wasn’t just for hiring a CSO...
  • E
    EDIT
    Until we get a golden cross when the 50 crosses the 200 we won't take off.
    Hopefully now that the market has decided to pump the sector again and stop holding the price down, we can see a push back above $45 and the 200 so we can get back into the 70's again. Can't do anything with this type of massive manipulation. You can only hope that data comes out that forces them to let the stock run as new demand comes in. Unfortunately when you play in a corrupt market you will have to get dirty sometimes and we are just now taking some small steps out of their (institutions, hedge funds) mud pit. Its been a long six months. We basically had a bear market when other stocks in other sectors have been very bullish. My calls don't expire until Jan 2022 so I have just been glancing at it and waiting for EDITAS to publish some positive findings and change the trend. We have to be patient but you don't do a media tour if you are bluffing so I expect big news to break in the next couple of months that will make it impossible for them to hold this stock this low again.
  • D
    Donato
    Back January, Editas’ leadership presented at the 39th Annual JP Morgan Healthcare Conference. At that time they mentioned that they expected to dose the first patent in the Advance Middle Dose cohort “within a few weeks”. Lisa Michaels (Editas Chief Scientific Officer) also stated that the earliest they expected to see some changes would probably be around the three month mark. But because of neural plasticity and because they are dosing patients with the most severe defect she noted that it certainly could take longer. Presuming the first mid-dose patient was dosed in mid-February, we should now be at the point where the patient’s vision may already be showing therapeutic benefits. Fingers crossed.
  • P
    Pub87
    Just hoping for a modest climb back up to -3% for the day. FIngers crossed.
  • A
    Anonymous
    Who’s ready for the run up to retest 100? 🙋‍♂️
    Bullish
  • S
    Sergey
    How many shares do I need to buy now to get 80 thousand dollars in 2030?)
    Neutral
  • O
    Offer
    Received an email from IB
    FYI: Changes in Analyst Ratings
    EDIT BUY +1
    Must say I do not see any info about it anywhere else but would be great to start seeing analysts thinking about Editas in a good way.
  • A
    Anonymous
    EDIT just received a parent for Cas9 in treatment of cystic fibrosis.
  • S
    Sean
    Another round-robin of stock options for the people who brought us from $99 to $35 in just 6 months. Where's mine?
  • n
    northnode3g
    @BlueRock Therapeutics announced a strategic research collaboration with Editas Medicine in 2019 to combine their cell and CRISPR technologies, respectively, to develop and produce novel enginereed cell therapies”

    https://crisprmedicinenews.com/news/ind-update-engineered-cell-therapy-for-parkinsons-disease/
  • i
    iamaverb
    The legal battle Broad vs CVC is heating up and is closing in on the finish line as CVC is trying to exclude previous statements that the PTAB relied on in their first interference decision.
    “CVC inventor Doudna was credited
    17 as saying: [‘]…. We weren’t sure if CRISPR/Cas9 would work in eukaryotes [’] …. Thus, even
    18 the CVC inventors, who could be considered to have had more skill than the ordinary artisans,
    19 were not sure if the eukaryotic chromatin would allow for a functional CRISPR-Cas9 system in a
    20 eukaryotic cell.”). CVC does not explain why its admissions here should be treated any differently
    21 and be excluded. They should not be. The CVC inventors were free to explain that their statements
    22 were not accurate—which they have not.
  • A
    Anonymous
    With such high volume, I will be irate if the company is selling their ATM secondary today. I don’t expect it to be the case, but I’d be incredibly disappointed.
  • A
    Anonymous
    This is breaking above 50 SMA. The 20 SMA is just below 34, the 50 is at 36.35, the 200 is at about 43.5. Looking for the 20 crossing above the 50 to give this enough oomph to break above the 200, then it could really go back to peer valuations without so much technical down pressure.
    Bullish
  • g
    grayfoxroving
    I've been watching this little colt eat oats for three years and finally it is ready to run thanks to sickle cell. I'm in and it's about time!